No Picture
News

Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference

MONMOUTH JUNCTION, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Gregory Adams, Ph.D., Chief Scientific Officer, will be presenting on Thursday, December 16th at 8:30am PST at the Antibody Engineering & Therapeutics Conference,… Click here to view original post… […]

No Picture
News

Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection

SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced that the first patients… Click here to view original post… […]

No Picture
News

Phanes Therapeutics TO PRESENT AT BIOTECH SHOWCASE™ 2022 IN SAN FRANCISCO Company expects to file three INDs in 2022

SAN DIEGO: SAN DIEGO, Dec. 15, 2021 /PRNewswire/ — Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery and development in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2022, to be held January 10–12, during the most important week in healthcare… Click here to view original post… […]

No Picture
News

Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting

SAN DIEGO and CALGARY, AB: – Treatment with intravenous pelareorep plus azacitidine reduced tumor burden – Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses SAN DIEGO and CALGARY, AB, Dec. 15, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical… Click here to view original post… […]

No Picture
News

Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research

SAN DIEGO–(BUSINESS WIRE)– #privacyengineering–Today, Gretel.ai announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, to create privacy-protected, synthetic genomic data that can be accessed by medical researchers anywhere. This announcement includes the release of a successful study the partnership conducted, which proves… Click here to view original post… […]

No Picture
News

Improving drug options for colorectal cancer patients

LA JOLLA—Patients with colorectal cancer were among the first to receive targeted therapies. These drugs aim to block the cancer-causing proteins that trigger out-of-control cell growth while sparing healthy tissues. But some patients are not eligible for these treatments because they have cancer-promoting mutations that are believed to cause resistance… Click here to view original post… […]

No Picture
News

Boston-based lab provider to open second Bay Area location

A Boston-based provider of lab space is tripling its footprint with the addition of a West Coast campus. SmartLabs, a company with labs in three different neighborhoods in the Boston area, will open a new research and manufacturing center that will be located in the heart of the South San… Click here to view original post… […]

No Picture
News

Arthrosi Therapeutics, Inc. Announces Patient Enrollment in Global Phase 2b Study of AR882

SAN DIEGO: SAN DIEGO, Dec. 14, 2021 /PRNewswire/ — Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced today patient enrollment in a global phase 2b study of AR882, its novel drug candidate. AR882 is a new uricosuric agent in clinical development for the management of hyperuricemia in patients with gout,… Click here to view original post… […]

No Picture
News

Immunicom Recruits Dr. Erdal Bozdo?an to Join Leadership Team

SAN DIEGO–(BUSINESS WIRE)– #biotech–Immunicom, Inc., a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, announced that Dr. Erdal Bozdo?an has joined Immunicom as the company’s General Manager in Turkey. Dr. Bozdo?an brings more than 22 years of medical affairs experience to the Immunicom team, having lent his expertise in product management, strategic planning,… Click here to view original post… […]

No Picture
News

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

SAN DIEGO: SAN DIEGO, Dec. 14, 2021 /PRNewswire/ — Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced its partner Aytu BioPharma (Nasdaq: AYTU), has received FDA clearance for its IND application for enzastaurin and also Orphan Drug Designation (ODD) for… Click here to view original post… […]

No Picture
Uncategorized

Principal scientist I– Chemical Biology – Novartis / GNF / San Diego, – Novartis – San Diego, CA

The successful candidate will have an enterprise-thinking mindset and will collaborate closely with multi-disciplinary teams within the organization.From Novartis – Tue, 14 Dec 2021 14:34:04 GMT – View all San Diego, CA jobsClick here to […]

No Picture
News

The Deerborne Group Unveils Insights on Demand Virtual Advisory Service

SAN DIEGO: SAN DIEGO, Dec. 14, 2021 /PRNewswire/ — The Deerborne Group, a global boutique management consulting firm, today announced the unveiling of their Insights on Demand virtual advisory service. The Deerborne Group recently formed their scientific advisory board (SAB), which is made up of internationally recognized key opinion leaders… Click here to view original post… […]

No Picture
News

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

SAN DIEGO & CAMBRIDGE, England–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary… Click here to view original post… […]